Cue Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Driehaus Capital Management LLC has disclosed beneficial ownership of 6.96% of Cue Biopharma, Inc.'s common stock, holding 292,144 shares.
NASDAQ
SCHEDULE 13G/A: Strome Entities Amend Passive Stake in Cue Biopharma, Disclosing 4.99% Beneficial Ownership
Mark E. Strome and affiliated entities have filed an amended Schedule 13G, revealing a collective beneficial ownership of 4.99% of Cue Biopharma, Inc.'s common stock, affirming a passive investment intent.
NASDAQ
SCHEDULE 13G/A: Bleichroeder Entities Reaffirm Significant Passive Stake in Cue Biopharma, Inc. with 9.99% Ownership
Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have filed an amended Schedule 13G, confirming their continued beneficial ownership of 9.99% of Cue Biopharma, Inc.'s common stock as of March 19, 2025.
NASDAQ
SCHEDULE 13G/A: Slate Path Capital LP and David Greenspan Amend Beneficial Ownership in Cue Biopharma, Holding 1.4% Stake
Slate Path Capital LP and David Greenspan have filed an amended Schedule 13G, disclosing a beneficial ownership of 1.4% in Cue Biopharma, Inc., primarily through shares issuable upon warrant exercise.